X

CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot

— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share

— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected

— Net loss before recognition of the deemed dividends was $5.3 million

— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018

— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin

— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Related Post